17/05/2024

Investing To Create Jobs And Save Lives

Avecho: First Patient Dosed in Phase III Insomnia Trial

PYC Therapeutics: RP11 CLINICAL TRIAL UPDATE – DOSING COMPLETED IN PATIENT COHORT 4

15/05/2024

Recce Pharmaceuticals: First Participants Dosed in Next Cohort Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial

Amplia Therapeutics Successfully Completes $4.27 million Fully Underwritten Entitlement Offer and ACCENT Trial Update

PYC Therapeutics: GLP TOX RESULTS CLEAR PATH FOR SECOND BLINDING EYE DISEASE DRUG TO ENTER HUMAN TRIALS

14/05/2024

BIOXYNE (ASX:BXN) AND CY BIOPHARMA FORGE STRATEGIC ALLIANCE TO DEVELOP NEW PSILOCYBIN THERAPIES IN AUSTRASIA

Noxopharm: Milestone reached as SOF-SKN™ progresses to next level

AdAlta: Cell Therapies Pty Ltd to be preferred manufacturer of cellular immunotherapies

Optiscan signs know-how agreement with Mayo Clinic

13/05/2024

MAYNE PHARMA ANNOUNCES GRANT OF TWO ADDITIONAL PATENTS FOR NEXTSTELLIS® ORAL CONTRACEPTIVE

10/05/2024

Recce: Positive Efficacy Data from Murdoch Children’s Research Institute in Pilot Study for Lung Infections

Neuren: DAYBUE™ Q1 2024 net sales US$75.9 million, full-year guidance US$370-420 million

Melodiol: Mernova’s Strong Progress Continues

Concussion medtech start-up kicks off raise for US expansion

08/05/2024

INVION SIGNS COLLABORATION AGREEMENT WITH MAJOR SOUTH KOREAN PHARMACEUTICAL GROUP HANLIM FOR THE TREATMENT OF GLIOBLASTOMA

Recce Pharmaceuticals: China Patent Granted for RECCE® Anti-Infectives

07/05/2024

Lumos achieves key Phase 1 milestone in Hologic fFN development agreement

02/05/2024

Careteq reaffirms EHS guidance and enhances HMR Platform

01/05/2024

Melodiol: Quarterly Activities Report: Melodiol delivers $4.4m in revenue during Q1 FY24 – a 91% increase the PCP

Melodiol: Appointment of Tim Tian as Group CFO

30/04/2024

Optiscan: QUARTERLY ACTIVITIES & CASHFLOW REPORT

Patrys: quarterly activities report and 4C quarterly cash flow report

Orthocell: Compelling 85% success rates from Remplir nerve repair study published in peer-reviewed clinical journal

Nyrada Commences Walter Reed Traumatic Brain Injury Study

Inoviq: THE WORLD RESEARCH COMMUNITY AND PROMEGA TO PROVE EXO-NET AS A PLATFORM TECHNOLOGY

Imugene: QUARTERLY ACTIVITIES & APPENDIX 4C CASH REPORT

LBT Innovations: QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 31 MARCH 2024

Clarity Pharma: Clarity Update: Complete response in first patient ever treated with two doses of Cu-67 SAR-bisPSMA at 8GBq

Starpharma: Quarterly Activities Report & Appendix 4C (ASX Announcement)

Amplia Therapeutics: QUARTERLY ACTIVITIES AND CASH FLOW REPORTS

Radiopharm Theranostics: Quarterly Activities & Cash Report and 4C for the quarter ended 31 March 2024

Clinuvel: SCENESSE® European Orphan Drug Designation for Xeroderma Pigmentosum (XP)

Noxopharm: March 2024 Quarterly Activities Report and Appendix 4C

Recce Pharmaceuticals: Safety Committee Approves High Dose of 4,000mg in Phase I/II Urinary Tract Infection/Urosepsis Rapid Infusion Clinical Tria

29/04/2024

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024

26/04/2024

Clarity successfully completes fully underwritten retail entitlement offer

25/04/2024

Neuren Pharmaceuticals: Q1 2024 Activity Report

23/04/2024

Trofinetide New Drug Submission for Rett Syndrome Accepted for Priority

Neuren Pharmaceuticals Limited: ANNUAL REPORT 2023

RADIOPHARM VENTURES INSTITUTIONAL & VENTURE CAPITAL PRESENTATION

22/04/2024

CLINUVEL expands global leadership team

Australian community organisations addressing viral hepatitis receive AU$400,000 via global Gilead ALL4LIVER Grant program – Gilead Sciences Australia

19/04/2024

Inoviq: OVARIAN CANCER TEST VALIDATION

18/04/2024

BIOXYNE LIMITED (ASX:BXN) RECEIVES FIRM COMMITMENTS TO RAISE $1.45 MILLION

MTP Connect: From mines to medicines: Australia’s radiopharmaceuticals future

17/04/2024

Medicinal cannabis company Little Green Pharma (ASX:LGP) records record quarterly revenue and cash receipts

Firebrick Pharma: Nasodine Nasal Spray Launch in the USA

Recce Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)

Island reports highly positive new data from ISLA-101 Single Ascending Dose study